The market for delta-like ligand 3 (DLL3) targeted therapies is rapidly expanding due to the rising prevalence of small cell lung cancer (SCLC) and neuroendocrine tumors. Advancements in antibody-drug conjugate (ADC) technology and increased clinical trial activity are driving the development of DLL3-targeted therapies. Strategic collaborations and growing interest from biopharma companies are accelerating market […]
Tag: cytokine
Robust Chronic Kidney Disease Pipeline: 75+ Key Pharma Companies Actively
Ziltivekimab, a proprietary anti-interleukin-6 ligand monoclonal antibody, targets residual inflammatory cardiovascular risk in advanced chronic kidney disease (CKD) patients. Developed as a therapy to reduce major cardiovascular adverse events in CKD patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients with moderate to severe CKD, ASCVD, and inflammation face high cardiovascular event risks with no […]